American Flag
LABOR DAY SALE

50% off your first year of any Quiver subscription

...

Use Promo Code:

LABOR26
Upgrade
American Flag

Sarepta Therapeutics,, Inc. Common Stock

SRPT Real Time Price USD
N/A
N/A
N/A
...
Overview
Financials
Forecast
Insiders
Institutions
Compensation
Government
Ownership
News

Chart provided by TradingView

SRPT historical prices
Income
Balance Sheet
Cash Flow
Revenue Breakdown
Congress Trading

Recent trades of SRPT by members of U.S. Congress

Politician Type Traded
Gilbert Ray Cisneros, Jr. House / D Sale $1,001 - $15,000 Apr 14, 2025
Josh Gottheimer House / D Purchase $1,001 - $15,000 Jul 14, 2023
Josh Gottheimer House / D Sale $1,001 - $15,000 Jun 13, 2023
Daniel S. Goldman House / D Sale $15,001 - $50,000 Apr 10, 2023
Josh Gottheimer House / D Purchase $1,001 - $15,000 Mar 06, 2023
Daniel S. Goldman House / D Purchase $15,001 - $50,000 Mar 06, 2023
Daniel S. Goldman House / D Sale $1,001 - $15,000 Jan 31, 2023
Josh Gottheimer House / D Sale $1,001 - $15,000 Nov 06, 2020
Gilbert Ray Cisneros, Jr. House / D Purchase $1,001 - $15,000 Sep 14, 2020
Gilbert Ray Cisneros, Jr. House / D Sale $1,001 - $15,000 Jun 10, 2020
Josh Gottheimer House / D Purchase $1,001 - $15,000 Dec 13, 2019
Gilbert Ray Cisneros, Jr. House / D Purchase $1,001 - $15,000 Oct 11, 2019
Gilbert Ray Cisneros, Jr. House / D Purchase $1,001 - $15,000 Oct 10, 2019
Gilbert Ray Cisneros, Jr. House / D Purchase $1,001 - $15,000 Apr 09, 2019
Gilbert Ray Cisneros, Jr. House / D Purchase $1,001 - $15,000 Mar 11, 2019
Gilbert Ray Cisneros, Jr. House / D Purchase $1,001 - $15,000 Feb 27, 2019
Gilbert Ray Cisneros, Jr. House / D Purchase $1,001 - $15,000 Feb 26, 2019
SRPT Stock Insider Trading Activity Follow @QuiverQuant for major insider updates

---

Closing Price
Purchase
Sale
Name
Type
Shares
Price
Shares Held
Date
Reported
SRPT Stock Institutional Owners
Investor
Shares
Change in Shares
Market Value
Date
Reported
SRPT Derivatives Institutional Owners
Investor
Type
Shares
Change in Shares
Market Value
Date
Reported
Whale Activity

Recently reported changes in SRPT holdings by institutional investors

Insider Trading

Quarterly net insider trading by SRPT's directors and management

* Insider trading data parsed from SEC Form 4 filings by Quiver Quantitative. Sign up for the Quiver API for real-time access.

About

Backtest Start Date
CAGR (Total)
Return (30d)
Return (1Y)
View Strategy Copytrade Strategy
  • 1M
  • 3M
  • 6M
  • YTD
  • 1Y
  • 2Y
  • 5Y
  • MAX

About

Backtest Start Date

Key Metrics

Return (1d)

Return (30d)

Return (1Y)

CAGR (Total)

Max Drawdown

Beta

Alpha

Sharpe Ratio

Win Rate

Average Win

Average Loss

Annual Volatility

Annual Std Dev

Information Ratio

Treynor Ratio

Total Trades

Show More
Metrics Definitions

Disclaimer: The performance results shown are based on historical backtesting and are hypothetical in nature. Backtested performance does not represent actual trading and does not account for all market factors that may affect execution, such as liquidity, slippage, and changing market conditions. Past performance is not necessarily indicative of future results. There is no guarantee that any trading strategy will be profitable or avoid losses.

  • Alpha

    Measures a portfolio's risk-adjusted performance against that of its benchmark

    Learn More about Alpha
  • Annual Standard Deviation

    Measures how much the portfolio's total return varies from its mean or average.

    Learn More about Annual Standard Deviation
  • Annual Volatility

    A statistical measure of the dispersion of returns for the portfolio.

    Learn More about Annual Volatility
  • Average Win

    The average return (%) for trades that resulted in a positive return.

  • Average Loss

    The average return (%) for trades that resulted in a negative return.

  • Beta

    A measure of the volatility of the portfolio compared to the market as a whole.

    Learn More about Beta
  • CAGR

    CAGR (Compounded Annual Growth Rate), is the historical annualized rate of return for an investment strategy, throughout the backtest period.

    Learn More about CAGR
  • Information Ratio

    A measurement of portfolio returns beyond the returns of its benchmark compared to the volatility of those returns.

    Learn More about Information Ratio
  • Max Drawdown

    the maximum observed loss from a peak to a trough of a portfolio, before a new peak is attained.

    Learn More about Max Drawdown
  • Sharpe Ratio

    The Sharpe Ratio is a measure of historical risk-adjusted return, which quantifies the amount of return that an investor received per unit of risk.

    Learn More about Sharpe Ratio
  • Total Trades

    The total number of trades made by this strategy.

  • Treynor Ratio

    Attempts to measure how successful an investment is in providing compensation to investors for taking on investment risk.

    Learn More about Treynor Ratio
  • Win Rate

    The percentage of total trades that resulted in a positive return.

Subscribe to Quiver Premium for insider trading alerts

Be the first to see our newest insights and key updates across all datasets.

See Pricing
schema-2
Corporate Lobbying

Government lobbying spending instances

  • $220,000 Jul 20, 2026 Issue: Budget/Appropriations Health Issues Science/Technology Trade (domestic/foreign)
  • $270,000 Apr 20, 2026 Issue: Health Issues Science/Technology
  • $230,000 Jan 20, 2026 Issue: Health Issues Science/Technology
  • $430,000 Oct 15, 2025 Issue: Health Issues Pharmacy Science/Technology Taxation/Internal Revenue Code
  • $260,000 Jul 16, 2025 Issue: Health Issues Science/Technology Taxation/Internal Revenue Code
  • $320,000 Apr 16, 2025 Issue: Health Issues Pharmacy Science/Technology Taxation/Internal Revenue Code
  • $290,000 Jan 16, 2025 Issue: Health Issues Pharmacy Science/Technology Taxation/Internal Revenue Code
  • $250,000 Oct 21, 2024 Issue: Science/Technology Taxation/Internal Revenue Code Health Issues
  • $240,000 Jul 19, 2024 Issue: Science/Technology Taxation/Internal Revenue Code Health Issues
  • $240,000 Jan 22, 2024 Issue: Taxation/Internal Revenue Code Health Issues
  • $290,000 Oct 19, 2023 Issue: Taxation/Internal Revenue Code Health Issues
  • $220,000 Jul 20, 2023 Issue: Taxation/Internal Revenue Code Health Issues
  • $180,000 Jan 19, 2023 Issue: Taxation/Internal Revenue Code Health Issues
  • $230,000 Oct 19, 2022 Issue: Taxation/Internal Revenue Code Health Issues
  • $120,000 Jul 20, 2022 Issue: Taxation/Internal Revenue Code Health Issues
  • $100,000 Apr 18, 2022 Issue: Health Issues
  • $140,000 Jan 19, 2022 Issue: Health Issues
  • $140,000 Oct 19, 2021 Issue: Health Issues
  • $150,000 Jul 20, 2021 Issue: Health Issues
  • $130,000 Apr 19, 2021 Issue: Health Issues
  • $130,000 Jan 20, 2021 Issue: Health Issues
  • $80,000 Oct 19, 2020 Issue: None
  • $140,000 Jul 17, 2020 Issue: Health Issues
  • $140,000 Apr 20, 2020 Issue: Health Issues
  • $150,000 Jan 16, 2020 Issue: Health Issues
  • $150,000 Oct 31, 2019 Issue: Health Issues
  • $150,000 Sep 24, 2019 Issue: Health Issues
  • $100,000 Sep 24, 2019 Issue: Health Issues
  • $150,000 Jan 18, 2019 Issue: Health Issues
  • $130,000 Oct 22, 2018 Issue: Health Issues
  • $130,000 Jul 19, 2018 Issue: Health Issues
  • $130,000 May 23, 2018 Issue: Health Issues Budget/Appropriations Medicare/Medicaid
  • $80,000 Apr 11, 2018 Issue: Health Issues Medicare/Medicaid Budget/Appropriations
  • $80,000 Oct 20, 2017 Issue: Medicare/Medicaid Health Issues Copyright/Patent/Trademark Budget/Appropriations
  • $80,000 Jul 25, 2017 Issue: Health Issues Budget/Appropriations Medicare/Medicaid
  • $80,000 Jun 06, 2017 Issue: Health Issues Medicare/Medicaid Budget/Appropriations
  • $80,000 Feb 16, 2017 Issue: Budget/Appropriations Health Issues Medicare/Medicaid
  • $80,000 Nov 23, 2016 Issue: Budget/Appropriations Health Issues Medicare/Medicaid
  • $80,000 Aug 03, 2016 Issue: Health Issues Medicare/Medicaid Budget/Appropriations
  • $110,000 Apr 20, 2016 Issue: Budget/Appropriations Health Issues Medicare/Medicaid
  • $110,000 Jan 20, 2016 Issue: Health Issues Budget/Appropriations Medicare/Medicaid Copyright/Patent/Trademark
  • $110,000 Nov 03, 2015 Issue: Budget/Appropriations Medicare/Medicaid Health Issues Copyright/Patent/Trademark
  • $110,000 Jul 20, 2015 Issue: Budget/Appropriations Health Issues Copyright/Patent/Trademark
  • $100,000 Apr 17, 2015 Issue: Budget/Appropriations Health Issues
  • $100,000 Feb 11, 2015 Issue: Health Issues Budget/Appropriations
  • $80,000 Oct 17, 2014 Issue: Budget/Appropriations Health Issues
  • $40,000 Jul 09, 2014 Issue: Health Issues
  • $40,000 Apr 15, 2014 Issue: Health Issues
Revolving Door

Former government officials who have lobbied for SRPT

27 former government officials from 15 congressional offices at 6 lobbying firms have lobbied for SRPT, most recently Jul 20, 2026.

  • Raissa Downs Senate Prin. Dep. Asst. Sec. for Leg. - HHS; Dep. Asst. Sec. for Leg. - HHS; Staff Dir., Sub. Cmte. on Employment, Sen. HELP Cmte. Formerly HELP Cmte. · TARPLIN, DOWNS & YOUNG, LLC · Jul 20, 2026
  • Jennifer Young Congress Asst. Sec. for Leg. - HHS; Dep. Asst. Sec. for Leg. - HHS; Cmte. Staff, House Cmte. on Ways and Means; Cmte. Staff, Sen. Cmte. on Finance Formerly Cmte. on Finance · TARPLIN, DOWNS & YOUNG, LLC · Jul 20, 2026
  • Tom Harkin
    Pamela Smith Senate Leg. Dir., Sen. Tom Harkin; Dep. Staff Dir., Senate HELP Cmte; Staff Dir., Senate HELP Cmte; Counselor to the Asst. AG, Civil Div., Dept of Justice; Spec Counsel, Ofc of Leg. Affairs, Dept of Justice; Counsel and LA, Senator Carol Moseley-Braun Formerly with Tom Harkin · TARPLIN, DOWNS & YOUNG, LLC · Jul 20, 2026
  • Ray LaHood
    Parick Carroll House Leg Asst. Rep. Ray LaHood, Leg Dir. Rep. Kevin Yoder, PSM Senate Appropriations Cmte. Formerly with Ray LaHood · TARPLIN, DOWNS & YOUNG, LLC · Jul 20, 2026
  • Steny H. Hoyer
    Elizabeth Murray House Senior Policy Advisor, Democratic Whip Steny Hoyer; Leg. Asst., Rep. Mike Thompson, Rep. Bob Matsui, and Sen. Bob Graham Formerly with Steny H. Hoyer · TARPLIN, DOWNS & YOUNG, LLC · Jul 20, 2026
  • Jim DeMint
    Charlotte Ivancic Senate Leg. Counsel, Sen. Jim DeMint; Health Counsel, Maj. Leader Bill Frist; Counsel and Budget Analyst, House Budget Cmte.; Asst. to the Speaker for Policy, Speaker John Boehner Formerly with Jim DeMint · TARPLIN, DOWNS & YOUNG, LLC · Jul 20, 2026
  • Emily Murry House Staff Dir., Sub. Cmte. on Helath, Ways and Means Cmte; Sr. Policy Adivsor, Maj. Leader McCarthy; Policy Advisor, Maj. Whip McCarthy; Prof. Staff, Republicans Study Cmte.; Leg. Aide, Rep. Ken Calvert; Leg. Asst., Rep. Tom Price Formerly Ken Calvert · TARPLIN, DOWNS & YOUNG, LLC · Jul 20, 2026
  • Kyrsten Sinema
    Margaret Joseph Senate CoS for Sen. Kyrsten Sinema, CoS for Rep. Kyrsten Sinema, CoS for Rep. Bobby Bright, CoS for Rep. Jim Matheson, Clerk for House Rules Cmte. Formerly with Kyrsten Sinema · TARPLIN, DOWNS & YOUNG, LLC · Jul 20, 2026
See all 27 on the Revolving Door dashboard
Corporate Lobbying

SRPT Estimated quarterly lobbying spending

Revenue Breakdown

SRPT Revenue by Segment or Geography

By Segment
By Geography
Quiver Logo

No Revenue by Segment data for this ticker

Revenue Breakdown Dashboard
Quiver Logo

No Revenue by Geography data for this ticker

Revenue Breakdown Dashboard
SRPT Income Statement
SRPT Balance Sheet
SRPT Cash Flow
U.S. Patents

New SRPT patent grants

  • Patent Title: Dose packaging system for medication and method of storing dose therein Jun. 16, 2026
  • Patent Title: Antisense antiviral compounds and methods for treating a filovirus infection May. 29, 2018
  • Patent Title: Induced exon inclusion in spinal muscle atrophy Apr. 17, 2018
  • Patent Title: Boronic acid conjugates of oligonucleotide analogues Mar. 20, 2018
  • Patent Title: Peptide oligonucleotide conjugates Jan. 09, 2018
  • Patent Title: Methods for treating progeroid laminopathies using oligonucleotide analogues targeting human lmna Dec. 05, 2017
  • Patent Title: Functionally-modified oligonucleotides and subunits thereof Oct. 17, 2017
  • Patent Title: Oligonucleotide analogues targeting human lmna Jun. 20, 2017
  • Patent Title: Antisense antibacterial method and compound Jan. 03, 2017
  • Patent Title: Compositions for treating muscular dystrophy Nov. 29, 2016
  • Patent Title: Antibacterial antisense oligonucleotide and method Nov. 22, 2016
  • Patent Title: Immunosuppression compound and treatment method Nov. 08, 2016
  • Patent Title: Antisense antibacterial method and compound Nov. 08, 2016
  • Patent Title: Oligonucleotide analogues having modified intersubunit linkages and/or terminal groups Oct. 18, 2016
  • Patent Title: Multiple exon skipping compositions for dmd Sep. 27, 2016
  • Patent Title: Multiple exon skipping compositions for dmd Sep. 20, 2016
  • Patent Title: Multiple exon skipping compositions for dmd Sep. 20, 2016
  • Patent Title: Multiple exon skipping compositions for dmd Sep. 06, 2016
  • Patent Title: Splice-region antisense composition and method Aug. 16, 2016
  • Patent Title: Antisense antiviral compound and method for treating influenza viral infection Jul. 19, 2016
  • Patent Title: Antisense antiviral compounds and methods for treating a filovirus infection Jul. 05, 2016
  • Patent Title: Oligonucleotide analog and method for treating flavivirus infections May. 24, 2016
  • Patent Title: Methods for treating progeroid laminopathies using oligonucleotide analogues targeting human lmna May. 03, 2016
  • Patent Title: Functionally-modified oligonucleotides and subunits thereof Mar. 08, 2016
  • Patent Title: Antibacterial antisense oligonucleotide and method Feb. 02, 2016
  • Patent Title: Antisense modulation of interleukins 17 and 23 signaling Jan. 19, 2016
  • Patent Title: Multiple exon skipping compositions for dmd Jan. 12, 2016
  • Patent Title: Exon skipping compositions for treating muscular dystrophy Dec. 22, 2015
  • Patent Title: Peptide oligonucleotide conjugates Oct. 20, 2015
  • Patent Title: Antisense modulation of nuclear hormone receptors Jun. 30, 2015
  • Patent Title: Oligonucleotide analogues targeting human lmna Jun. 30, 2015
  • Patent Title: Immunosuppression compound and treatment method Jan. 13, 2015
  • Patent Title: Antisense antiviral compound and method for treating ssrna viral infection Dec. 09, 2014
  • Patent Title: Splice-region antisense composition and method Nov. 25, 2014
  • Patent Title: Peptide conjugated, inosine-substituted antisense oligomer compound and method Nov. 04, 2014
  • Patent Title: Multiple exon skipping compositions for dmd Oct. 28, 2014
  • Patent Title: Multiple exon skipping compositions for dmd Oct. 21, 2014
  • Patent Title: Compound and method for treating myotonic dystrophy Sep. 16, 2014
  • Patent Title: Antisense composition and method for treating muscle atrophy Jul. 22, 2014
  • Patent Title: Antisense antiviral agent and method for treating ssrna viral infection Jul. 22, 2014
  • Patent Title: Oligonucleotide analogues having modified intersubunit linkages and/or terminal groups Jul. 15, 2014
  • Patent Title: Oligonucleotide compound and method for treating nidovirus infections Jun. 24, 2014
  • Patent Title: Compound and method for treating myotonic dystrophy Jun. 03, 2014
  • Patent Title: Antisense antiviral compounds and methods for treating a filovirus infection Apr. 22, 2014
  • Patent Title: Antisense antiviral compound and method for treating influenza viral infection Apr. 15, 2014
  • Patent Title: Oligonucleotide analog and method for treating flavivirus infections Dec. 31, 2013
  • Patent Title: Antisense compositions and methods for modulating contact hypersensitivity or contact dermatitis Nov. 26, 2013
  • Patent Title: Antibacterial antisense oligonucleotide and method Sep. 17, 2013
  • Patent Title: Method for treating enterovirus or rhinovirus infection using antisense antiviral compounds Sep. 03, 2013
  • Patent Title: Immunosuppression compound and treatment method Aug. 06, 2013
Government Contracts

Federal grants, loans, and purchases

Quiver Logo

No Government Contracts for this ticker

Government Contracts Dashboard
Government Contracts

Estimated quarterly amount awarded to SRPT from public contracts

Quiver Logo

No recent Government Contracts for this ticker

Government Contracts Dashboard
SRPT News

Recent insights relating to SRPT

CNBC Recommendations

Recent picks made for SRPT stock on CNBC

Top ETF Holders

ETFs with the largest estimated holdings in SRPT

SRPT Analyst Ratings

SRPT Stock Forecasts
...

  • ... Highest Price Target
  • ... Median Price Target
  • ... Lowest Price Target
SRPT Analyst Forecasts
Analyst
Firm
Current
Previous
Date
Frequently Asked Questions
  • Is $SRPT stock a Buy, Sell, or Hold?

  • What is the price target for $SRPT stock?

* Analyst consensus is not financial advice. Please see our data disclaimers .

SRPT Top Shareholders
Shareholder
Shares Held
SRPT Options Owners
Shareholder
Security
Underlying Shares
Frequently Asked Questions
  • Who owns $SRPT stock?

  • Who owns the most shares of $SRPT stock?

  • What funds own $SRPT stock?

* These are estimates based on data taken from SEC filings. There may be inaccuracies due to parsing errors, accidental double-counting, incorrect classification of indirectly owned shares, or any other number of issues.

SRPT Stock Smart Score

The Quiver Smart Score combines our data on Congress Trading, Lobbying, Insider Trading, CNBC Mentions and more to provide a comprehensive view of the strength of a stock's underlying data.

The Smart Score grades stocks on a scale of 1 (weakest) to 10 (strongest) based on the strength of the underlying data.
?

Sign Up to view SRPT Smart Score

Score Breakdown
Bull Case vs Bear Case

See concise summaries of analyst reports, presenting both bullish and bearish arguments for a stock.

Example:

Bulls Say:

The Bulls Say summary highlights positive aspects of the stock.

Bears Say:

The Bears Say summary points out potential risks and negative aspects of the stock.

Show More
About SRPT

Sarepta Therapeutics Inc is a commercial-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, gene therapies, and other genetic medicines for rare diseases, particularly neuromuscular disorders. The company has developed approved treatments for Duchenne muscular dystrophy, including EXONDYS 51, VYONDYS 53, AMONDYS 45, and ELEVIDYS, and is advancing additional therapeutic candidates for neuromuscular and other rare diseases. The company operates in one segment: discovering, developing, manufacturing, and delivering therapies to patients with rare diseases.

  • Address Cambridge, MA
  • Market Cap 2.0 billion
  • Employees 835
  • Industrial Classification Pharmaceutical Preparations

Sarepta Therapeutics,, Inc. Common Stock (SRPT) Historical Stock Prices

Sarepta Therapeutics,, Inc. Common Stock (SRPT) closed at $18.95 on September 23, 2026. Over the past year its adjusted close ranged from $14.86 to $24.45. Daily prices go back to January 2, 2014, 3,198 trading days in all.

  • 1 month+4.52%
  • 3 months+13.51%
  • Year to date-11.94%
  • 1 year+5.69%
  • 3 years-84.20%
  • 5 years-79.08%
  • Max-7.92%
See every congressional and insider trade on the SRPT price chart

Quiver Premium charts SRPT's full daily history since 2014 with each congressional purchase and sale and every open-market insider purchase marked on the price line, with hover details for each trade.

Upgrade to Premium

Last 12 months, newest first

Access Raw Data Daily prices since 2014 for every ticker, through the Quiver API
DateOpenHighLowCloseAdj. CloseVolume
Sep 23, 2026 20.72 20.76 18.73 18.95 18.95 3,757,657
Sep 22, 2026 20.46 21.18 20.19 20.81 20.81 2,193,201
Sep 21, 2026 20.29 20.50 19.96 20.14 20.14 1,756,604
Sep 18, 2026 20.63 20.74 19.62 20.11 20.11 6,292,414
Sep 17, 2026 20.23 21.75 19.97 20.67 20.67 2,588,120
Sep 16, 2026 20.68 20.89 19.72 19.76 19.76 2,509,698
Sep 15, 2026 20.81 21.06 20.29 20.72 20.72 2,534,749
Sep 14, 2026 20.55 21.40 20.38 20.92 20.92 2,192,972
Sep 11, 2026 20.76 21.10 20.29 20.45 20.45 1,810,736
Sep 10, 2026 22.02 22.02 20.28 20.52 20.52 2,204,294
Sep 9, 2026 20.80 23.22 20.63 22.02 22.02 4,167,542
Sep 8, 2026 19.86 21.32 19.51 20.94 20.94 6,242,673
Sep 4, 2026 22.58 22.64 21.98 22.50 22.50 2,955,533
Sep 3, 2026 23.15 23.34 22.42 22.99 22.99 2,768,345
Sep 2, 2026 21.33 23.62 21.33 23.21 23.21 4,807,157
Sep 1, 2026 20.88 21.82 20.55 21.33 21.33 2,623,726
Aug 31, 2026 20.56 21.16 20.18 21.03 21.03 2,656,894
Aug 28, 2026 21.49 22.58 20.83 20.86 20.86 3,612,385
Aug 27, 2026 19.35 22.59 18.77 21.59 21.59 7,921,140
Aug 26, 2026 18.74 19.48 18.31 19.46 19.46 2,409,799
Aug 25, 2026 18.42 19.05 18.19 18.92 18.92 1,696,520
Aug 24, 2026 18.53 18.70 17.90 18.13 18.13 1,381,271
Aug 21, 2026 19.39 19.73 18.66 18.79 18.79 1,674,597
Aug 20, 2026 19.42 19.95 18.59 19.22 19.22 2,913,417
Aug 19, 2026 18.74 20.19 18.74 19.73 19.73 4,943,337
Aug 18, 2026 18.17 18.29 17.88 18.02 18.02 1,600,161
Aug 17, 2026 17.93 18.30 17.72 18.18 18.18 1,728,692
Aug 14, 2026 18.22 18.26 17.69 18.10 18.10 1,561,239
Aug 13, 2026 18.41 18.73 18.20 18.42 18.42 2,518,301
Aug 12, 2026 18.06 18.48 17.86 18.38 18.38 2,369,421
Aug 11, 2026 17.23 18.25 17.23 18.22 18.22 3,002,762
Aug 10, 2026 16.53 17.21 16.38 17.18 17.18 2,696,719
Aug 7, 2026 16.86 17.26 16.47 16.78 16.78 3,064,146
Aug 6, 2026 16.66 17.19 16.35 16.78 16.78 5,241,391
Aug 5, 2026 16.43 16.75 15.82 15.93 15.93 3,109,305
Aug 4, 2026 16.00 16.45 15.64 16.39 16.39 2,878,687
Aug 3, 2026 15.09 15.89 14.75 15.88 15.88 3,799,658
Jul 31, 2026 15.50 15.64 14.84 14.86 14.86 3,603,368
Jul 30, 2026 15.54 15.65 15.04 15.56 15.56 3,024,025
Jul 29, 2026 15.43 15.86 15.09 15.54 15.54 2,860,568
Jul 28, 2026 15.74 15.97 15.04 15.43 15.43 3,533,426
Jul 27, 2026 16.46 16.69 15.88 15.89 15.89 3,701,422
Jul 24, 2026 15.88 16.03 15.49 15.68 15.68 2,141,883
Jul 23, 2026 15.57 16.02 15.43 15.88 15.88 2,485,535
Jul 22, 2026 16.20 16.37 15.81 15.82 15.82 2,426,944
Jul 21, 2026 16.81 17.22 16.02 16.21 16.21 4,123,318
Jul 20, 2026 17.39 17.70 16.83 16.83 16.83 1,777,090
Jul 17, 2026 16.66 17.68 16.65 17.22 17.22 5,399,159
Jul 16, 2026 17.61 17.82 17.22 17.23 17.23 3,180,760
Jul 15, 2026 18.05 18.13 17.02 17.61 17.61 3,508,809
Jul 14, 2026 18.85 18.85 17.94 17.96 17.96 2,962,206
Jul 13, 2026 18.97 19.36 18.52 18.82 18.82 2,457,719
Jul 10, 2026 20.54 20.54 18.68 18.95 18.95 3,030,126
Jul 9, 2026 20.39 20.88 20.05 20.52 20.52 3,008,326
Jul 8, 2026 19.73 20.30 19.36 20.21 20.21 3,311,711
Jul 7, 2026 19.27 19.85 18.63 19.79 19.79 2,434,887
Jul 6, 2026 19.21 19.63 18.74 19.18 19.18 2,846,785
Jul 2, 2026 18.41 19.56 18.03 19.28 19.28 4,358,120
Jul 1, 2026 18.23 18.41 17.45 18.20 18.20 3,426,200
Jun 30, 2026 17.50 18.19 16.90 17.97 17.97 4,213,974
Jun 29, 2026 16.86 17.40 16.43 17.02 17.02 3,803,854
Jun 26, 2026 15.79 16.92 15.79 16.85 16.85 20,026,919
Jun 25, 2026 16.73 16.84 15.94 16.02 16.02 2,541,710
Jun 24, 2026 17.26 17.41 16.69 16.70 16.70 2,746,790
Jun 23, 2026 17.33 17.80 17.22 17.26 17.26 2,371,699
Jun 22, 2026 17.82 18.18 17.50 17.65 17.65 2,354,966
Jun 18, 2026 17.05 18.01 17.05 17.53 17.53 5,610,425
Jun 17, 2026 16.16 17.92 16.16 16.96 16.96 4,512,853
Jun 16, 2026 15.77 16.00 15.39 15.78 15.78 2,195,676
Jun 15, 2026 15.68 16.09 15.57 15.77 15.77 2,311,747
Jun 12, 2026 15.01 15.55 15.01 15.31 15.31 2,270,569
Jun 11, 2026 15.02 15.16 14.68 15.00 15.00 2,758,816
Jun 10, 2026 15.56 16.05 15.02 15.11 15.11 2,332,214
Jun 9, 2026 15.87 16.28 15.41 15.89 15.89 2,437,071
Jun 8, 2026 15.77 15.97 15.42 15.55 15.55 2,426,430
Jun 5, 2026 16.59 16.69 15.66 15.75 15.75 2,739,948
Jun 4, 2026 16.49 16.90 16.46 16.66 16.66 2,339,342
Jun 3, 2026 16.25 16.52 16.10 16.24 16.24 3,542,639
Jun 2, 2026 17.60 17.61 15.95 16.25 16.25 4,609,962
Jun 1, 2026 17.59 18.21 17.40 17.61 17.61 3,098,307
May 29, 2026 17.42 17.99 17.42 17.87 17.87 3,654,619
May 28, 2026 16.61 17.36 16.61 17.30 17.30 2,931,981
May 27, 2026 16.81 17.05 16.53 16.68 16.68 2,191,205
May 26, 2026 16.89 17.00 16.42 16.67 16.67 3,092,834
May 22, 2026 16.90 17.21 16.76 16.80 16.80 1,959,125
May 21, 2026 16.73 17.24 16.66 16.96 16.96 2,021,567
May 20, 2026 16.79 17.26 16.57 17.12 17.12 2,296,614
May 19, 2026 17.01 17.10 16.59 16.64 16.64 2,292,425
May 18, 2026 17.76 17.96 16.85 17.01 17.01 3,902,855
May 15, 2026 18.43 18.68 17.52 17.55 17.55 4,571,082
May 14, 2026 19.32 19.42 18.65 18.68 18.68 3,284,753
May 13, 2026 19.00 19.33 18.65 18.84 18.84 3,415,231
May 12, 2026 19.40 19.49 18.84 19.13 19.13 2,830,459
May 11, 2026 19.99 20.99 19.27 19.40 19.40 3,072,520
May 8, 2026 20.75 20.84 19.87 19.95 19.95 4,078,406
May 7, 2026 22.25 22.68 20.13 20.80 20.80 5,144,907
May 6, 2026 22.12 23.49 21.64 23.03 23.03 4,784,950
May 5, 2026 22.37 22.66 21.04 21.79 21.79 2,191,318
May 4, 2026 21.18 22.16 21.18 22.04 22.04 2,594,374
May 1, 2026 20.93 21.66 20.92 21.49 21.49 2,428,738
Apr 30, 2026 20.97 21.19 20.56 20.88 20.88 1,748,369
Apr 29, 2026 20.89 20.89 20.30 20.67 20.67 1,450,290
Apr 28, 2026 21.00 21.35 20.80 21.07 21.07 2,247,971
Apr 27, 2026 20.22 21.11 20.22 20.98 20.98 3,139,483
Apr 24, 2026 20.65 20.68 19.93 20.30 20.30 2,076,721
Apr 23, 2026 20.40 20.54 18.38 20.42 20.42 4,956,144
Apr 22, 2026 21.06 21.10 20.39 20.64 20.64 2,565,221
Apr 21, 2026 21.50 21.56 20.52 20.68 20.68 3,092,743
Apr 20, 2026 21.38 21.49 20.81 21.42 21.42 2,807,383
Apr 17, 2026 21.23 21.75 21.02 21.55 21.55 2,512,120
Apr 16, 2026 21.75 22.02 20.76 21.17 21.17 2,572,242
Apr 15, 2026 22.43 22.49 21.55 21.73 21.73 2,135,892
Apr 14, 2026 21.95 22.43 21.76 22.15 22.15 2,294,685
Apr 13, 2026 21.19 21.84 20.83 21.79 21.79 1,926,578
Apr 10, 2026 22.24 22.25 21.14 21.18 21.18 1,993,617
Apr 9, 2026 21.90 22.66 21.80 22.23 22.23 1,884,688
Apr 8, 2026 23.66 23.70 21.80 21.90 21.90 2,717,562
Apr 7, 2026 22.65 23.21 22.02 23.08 23.08 1,883,835
Apr 6, 2026 23.42 23.84 22.71 22.80 22.80 2,257,986
Apr 2, 2026 21.93 23.29 21.61 23.23 23.23 3,157,599
Apr 1, 2026 21.92 22.66 21.65 22.13 22.13 2,074,582
Mar 31, 2026 20.72 22.11 20.72 21.76 21.76 2,298,727
Mar 30, 2026 19.93 20.62 19.81 20.48 20.48 2,924,001
Mar 27, 2026 21.67 21.67 19.71 19.97 19.97 4,609,422
Mar 26, 2026 23.15 23.20 21.36 21.68 21.68 7,565,152
Mar 25, 2026 19.76 23.85 19.67 23.77 23.77 17,077,287
Mar 24, 2026 17.49 17.85 17.25 17.61 17.61 2,201,723
Mar 23, 2026 16.93 17.80 16.67 17.71 17.71 2,942,742
Mar 20, 2026 16.68 17.33 16.53 16.69 16.69 2,864,089
Mar 19, 2026 16.94 17.18 16.45 16.65 16.65 2,812,513
Mar 18, 2026 16.58 17.25 16.50 17.16 17.16 1,756,562
Mar 17, 2026 16.65 17.33 16.65 16.84 16.84 1,425,607
Mar 16, 2026 16.50 16.90 16.27 16.66 16.66 1,903,857
Mar 13, 2026 17.47 17.59 16.39 16.40 16.40 2,291,689
Mar 12, 2026 17.45 17.45 16.74 17.04 17.04 2,116,484
Mar 11, 2026 17.54 17.58 16.60 17.57 17.57 2,449,127
Mar 10, 2026 17.63 18.20 17.42 17.66 17.66 2,732,288
Mar 9, 2026 16.82 17.71 16.57 17.64 17.64 3,725,892
Mar 6, 2026 15.86 16.88 15.53 16.71 16.71 3,069,287
Mar 5, 2026 16.06 16.61 15.99 16.23 16.23 2,486,480
Mar 4, 2026 16.08 16.43 15.70 16.09 16.09 2,072,963
Mar 3, 2026 15.96 16.30 15.75 15.87 15.87 2,015,676
Mar 2, 2026 16.28 16.68 15.84 16.32 16.32 2,510,243
Feb 27, 2026 17.17 17.26 16.46 16.76 16.76 2,620,499
Feb 26, 2026 17.80 17.89 16.41 17.45 17.45 6,179,964
Feb 25, 2026 18.86 19.25 18.73 18.97 18.97 2,241,852
Feb 24, 2026 18.44 19.13 18.36 18.84 18.84 2,560,734
Feb 23, 2026 18.72 19.01 18.02 18.12 18.12 1,252,885
Feb 20, 2026 18.39 18.94 18.15 18.88 18.88 1,493,996
Feb 19, 2026 18.36 18.68 18.02 18.59 18.59 1,420,666
Feb 18, 2026 17.94 18.53 17.70 18.38 18.38 2,014,890
Feb 17, 2026 17.73 18.00 17.45 17.88 17.88 1,427,818
Feb 13, 2026 17.56 18.19 17.50 17.79 17.79 1,554,996
Feb 12, 2026 17.96 18.09 17.24 17.40 17.40 1,578,057
Feb 11, 2026 18.29 18.46 17.45 17.96 17.96 1,851,169
Feb 10, 2026 18.36 18.69 18.10 18.33 18.33 1,750,464
Feb 9, 2026 18.36 18.61 17.90 18.31 18.31 1,861,143
Feb 6, 2026 17.59 18.64 17.51 18.50 18.50 3,173,590
Feb 5, 2026 19.58 19.75 16.89 17.03 17.03 6,011,295
Feb 4, 2026 20.30 20.71 19.70 19.73 19.73 2,398,238
Feb 3, 2026 20.76 21.36 19.92 20.28 20.28 1,880,434
Feb 2, 2026 20.01 20.98 19.62 20.72 20.72 1,870,207
Jan 30, 2026 21.05 21.31 20.22 20.34 20.34 3,121,956
Jan 29, 2026 21.32 21.85 20.85 21.23 21.23 2,125,075
Jan 28, 2026 22.14 22.14 21.26 21.31 21.31 2,310,298
Jan 27, 2026 22.30 23.22 22.06 22.17 22.17 2,570,934
Jan 26, 2026 21.96 24.68 21.26 22.80 22.80 6,990,971
Jan 23, 2026 21.89 22.60 21.03 21.13 21.13 4,973,365
Jan 22, 2026 21.37 21.81 21.06 21.79 21.79 2,033,328
Jan 21, 2026 20.97 21.88 20.90 21.37 21.37 2,281,437
Jan 20, 2026 20.53 21.22 20.10 21.04 21.04 1,740,252
Jan 16, 2026 21.25 21.51 20.81 21.13 21.13 2,269,513
Jan 15, 2026 22.68 22.70 21.01 21.31 21.31 3,145,505
Jan 14, 2026 21.56 23.00 20.94 22.80 22.80 3,134,793
Jan 13, 2026 21.25 21.96 21.14 21.46 21.46 3,162,063
Jan 12, 2026 23.93 24.05 20.21 21.14 21.14 6,592,605
Jan 9, 2026 23.67 23.89 23.05 23.83 23.83 2,039,990
Jan 8, 2026 23.23 24.12 22.90 23.15 23.15 3,063,589
Jan 7, 2026 22.50 24.10 22.17 23.46 23.46 3,293,620
Jan 6, 2026 21.14 22.55 21.14 22.35 22.35 3,789,439
Jan 5, 2026 21.40 21.97 20.86 21.07 21.07 2,978,534
Jan 2, 2026 21.92 22.00 21.20 21.31 21.31 1,896,080
Dec 31, 2025 21.45 21.77 21.33 21.52 21.52 1,845,157
Dec 30, 2025 21.79 21.91 21.40 21.49 21.49 2,088,127
Dec 29, 2025 21.81 21.96 21.36 21.82 21.82 2,669,613
Dec 26, 2025 22.36 22.41 21.86 22.12 22.12 1,392,725
Dec 24, 2025 21.96 22.46 21.82 22.32 22.32 1,254,186
Dec 23, 2025 21.19 22.52 21.09 22.00 22.00 2,784,503
Dec 22, 2025 20.87 21.53 20.86 21.23 21.23 2,314,700
Dec 19, 2025 20.33 21.48 20.33 21.04 21.04 6,507,639
Dec 18, 2025 21.15 21.64 20.14 20.34 20.34 2,381,544
Dec 17, 2025 22.29 22.42 21.05 21.14 21.14 2,540,445
Dec 16, 2025 21.49 22.97 21.35 22.31 22.31 3,644,495
Dec 15, 2025 21.88 22.34 20.93 21.55 21.55 3,230,942
Dec 12, 2025 21.72 21.74 21.18 21.53 21.53 2,008,799
Dec 11, 2025 21.07 21.96 20.76 21.75 21.75 4,775,544
Dec 10, 2025 22.11 22.67 21.84 22.20 22.20 3,103,524
Dec 9, 2025 22.46 22.85 21.85 22.17 22.17 2,223,202
Dec 8, 2025 22.53 22.67 21.44 21.86 21.86 3,809,596
Dec 5, 2025 22.89 22.93 21.95 22.26 22.26 2,659,310
Dec 4, 2025 21.55 23.00 21.47 22.82 22.82 3,395,986
Dec 3, 2025 19.75 21.93 19.43 21.84 21.84 3,472,695
Dec 2, 2025 19.82 20.53 19.37 20.47 20.47 4,003,944
Dec 1, 2025 20.84 21.00 19.67 19.72 19.72 2,857,543
Nov 28, 2025 21.12 21.38 20.72 21.34 21.34 1,633,037
Nov 26, 2025 19.40 21.21 19.35 20.95 20.95 3,246,891
Nov 25, 2025 18.91 19.45 18.73 19.35 19.35 3,000,137
Nov 24, 2025 17.76 19.14 17.61 18.91 18.91 4,427,277
Nov 21, 2025 16.40 17.72 16.33 17.69 17.69 3,939,883
Nov 20, 2025 16.69 17.60 16.31 16.48 16.48 4,640,030
Nov 19, 2025 17.41 17.43 15.94 16.39 16.39 4,398,183
Nov 18, 2025 17.38 17.73 16.94 17.44 17.44 3,717,901
Nov 17, 2025 18.61 18.70 17.38 17.54 17.54 4,451,372
Nov 14, 2025 17.51 20.15 17.51 18.81 18.81 8,044,554
Nov 13, 2025 17.70 18.35 17.50 17.82 17.82 3,473,763
Nov 12, 2025 18.05 18.63 17.60 18.00 18.00 4,050,171
Nov 11, 2025 17.27 18.30 16.90 17.98 17.98 4,388,893
Nov 10, 2025 18.12 18.13 17.26 17.27 17.27 3,452,782
Nov 7, 2025 17.77 17.95 16.55 17.63 17.63 4,187,428
Nov 6, 2025 18.64 18.75 17.41 17.64 17.64 6,572,497
Nov 5, 2025 16.59 18.80 16.58 18.67 18.67 11,144,588
Nov 4, 2025 15.24 17.75 15.08 16.20 16.20 23,907,332
Nov 3, 2025 24.27 24.55 22.67 24.45 24.45 15,620,958
Oct 31, 2025 23.42 24.48 23.02 24.01 24.01 4,509,780
Oct 30, 2025 23.22 23.39 22.79 23.25 23.25 3,421,285
Oct 29, 2025 24.02 24.09 23.15 23.45 23.45 3,722,509
Oct 28, 2025 23.48 24.40 23.27 24.22 24.22 3,435,956
Oct 27, 2025 23.29 24.24 23.06 23.50 23.50 4,042,396
Oct 24, 2025 21.94 23.43 21.80 22.81 22.81 3,731,023
Oct 23, 2025 21.80 22.27 21.29 21.89 21.89 4,478,289
Oct 22, 2025 23.20 23.72 22.29 22.47 22.47 3,707,731
Oct 21, 2025 23.07 23.54 22.77 23.35 23.35 2,867,083
Oct 20, 2025 23.00 23.73 22.80 23.05 23.05 4,020,617
Oct 17, 2025 22.83 22.99 21.93 22.51 22.51 4,474,628
Oct 16, 2025 22.25 23.87 22.22 23.34 23.34 6,055,539
Oct 15, 2025 21.74 22.26 21.52 22.20 22.20 3,472,043
Oct 14, 2025 21.58 21.82 20.92 21.43 21.43 3,747,051
Oct 13, 2025 22.00 22.48 21.50 21.96 21.96 4,034,170
Oct 10, 2025 23.15 23.19 22.09 22.11 22.11 4,609,538
Oct 9, 2025 23.44 24.18 23.05 23.13 23.13 5,315,375
Oct 8, 2025 24.18 25.32 22.64 23.38 23.38 10,535,420
Oct 7, 2025 23.36 23.88 22.56 23.12 23.12 4,772,453
Oct 6, 2025 23.15 23.59 22.30 23.26 23.26 6,171,963
Oct 3, 2025 22.37 22.95 21.82 22.64 22.64 8,323,605
Oct 2, 2025 19.57 23.42 19.57 22.35 22.35 15,428,803
Oct 1, 2025 18.88 20.05 18.88 19.32 19.32 4,729,501
Sep 30, 2025 18.67 19.34 18.14 19.27 19.27 5,529,490
Sep 29, 2025 18.17 19.28 18.14 18.82 18.82 6,602,104
Sep 26, 2025 17.64 18.39 17.57 18.36 18.36 4,060,288
Sep 25, 2025 18.09 18.24 17.65 17.72 17.72 4,264,773
Sep 24, 2025 18.15 18.46 17.51 18.26 18.26 5,145,298
Sep 23, 2025 18.72 19.05 17.88 17.93 17.93 5,589,923

Open, high, low and close are the prices as traded. Adjusted close accounts for splits and dividends, and is what the chart and returns use. Where a company changed its ticker, its history under the old symbol is included.

Need daily prices for every ticker, in code?

The Quiver API serves daily prices back to 2014 alongside congressional trades, insider trades, 13F holdings and lobbying, all under one key and inside Claude or ChatGPT through our MCP server.

Explore the Quiver API
Sarepta Therapeutics,, Inc. Common Stock Executive Compensation

We estimate that -- received a compensation of -- in --, making them the highest paid executive at SRPT, per a recent SEC DEF 14A filing. We estimate that the median employee at Sarepta Therapeutics, Inc. is paid $292,690.



Name
Role
Salary
Bonus
Stock/Option Awards
Total Compensation